

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

**VOLUNTARY ANNOUNCEMENT
SKYWALKER ORTHOPEDIC SURGICAL ROBOT
OBTAINED THE ANVISA CERTIFICATION IN BRAZIL**

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce that the SkyWalker Orthopedic Surgical Robot (overseas product name: SkyWalker™, “**SkyWalker**”) independently developed by the Group has passed the review of the Brazilian Health Regulatory Agency (“**ANVISA**”) and has been approved for marketing in Brazil. This represents another important progress of SkyWalker made by the Group after the successive obtaining of the marketing approval from the National Medical Products Administration (the “**NMPA**”), the clearance from the U.S. Food and Drug Administration (the “**FDA**”) and the CE Mark last year.

ABOUT SKYWALKER

SkyWalker enjoys technical advantages such as precise operation, efficient synergy, safety protection and strong compatibility. Before surgery, its planning system can assist surgeons to formulate personalized prosthesis implantation plans based on patients’ preoperative CT scan data and prosthesis model data. During surgery, the precise positioning from surgical planning and the utilization of registration technology in combination with the self-developed highly dexterous and lightweight robotic arm(s) allow for an osteotomy to be quickly completed, thus helping to improve the accuracy and efficiency of the operation. SkyWalker avoids the need for positioning of the medullary cavity in traditional surgery. As there is no intramedullary rod implantation during the surgery, SkyWalker reduces surgical damage and blood loss, improves the postoperative lower limb alignment, reduces surgical complications, and helps patients achieve faster recovery after surgery.

IMPACT ON THE COMPANY

As the first and only domestic surgical robot that has obtained the approval from the NMPA, FDA, CE Mark and ANVISA, SkyWalker has shown the excellent technical strength and product advantages of domestic surgical robots, accelerating the Group's strategy for globalisation. In recent years, SkyWalker has persisted in challenging complicated surgical procedures and helping clinical specialists achieve numerous breakthroughs. To date, more than 400 robot-assisted clinical trial surgeries have been accomplished by SkyWalker in the orthopedics, joint surgery and sports medicine departments of 27 hospitals in 15 provinces and municipalities in China. These surgeries include a number of innovative and challenging robot-assisted procedures, such as the first 5G remote joint replacement surgery with the domestic surgical robot, the joint replacement surgery of internal fixation by intramedullary nail for fractures of femoral shaft (股骨幹骨折髓內釘內固定術後關節置換手術) and the joint replacement surgery for severe rheumatoid arthritis (重度類風濕關節炎關節置換手術), etc. As for international development, SkyWalker successfully completed dozens of cases of the application in total knee replacement surgeries in various hospitals in the United States, including the Lighthouse Surgical Suites, LLC in Hollis, New Hampshire, USA. The above success evidenced the gradual maturation of SkyWalker in clinical application providing physicians and patients around the world with better, more reliable and more comprehensive robotic surgical solutions, and realising the belief of "make surgery easier, safer and less invasive".

Shareholders of the Company and potential investors are advised to exercise caution when dealing in shares of the Company.

By Order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Chairman
Mr. Sun Hongbin

Shanghai, China, 4 May 2023

As at the date of this announcement, the executive director of the Company is Dr. He Chao, the non-executive directors of the Company are Mr. Sun Hongbin, Mr. Sun Xin and Mr. Chen Chen, and the independent non-executive directors of the Company are Dr. Li Minghua, Mr. Yao Haisong and Mr. Mui Wing Hong.